+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment interruptions in HIV-infected subjects

Treatment interruptions in HIV-infected subjects

Journal of Antimicrobial ChemoTherapy 58(3): 502-505

Despite a high antiviral efficacy, the use of highly active antiretroviral therapy (HAART) in clinical practice is often impaired by the long-term toxicity of antiretroviral treatment, the increased rate of human immunodeficiency virus-1 (HIV-1) drug resistance in treated patients and the cost of therapies, so that possible interruption of HAART has to be considered as part of the current clinical practice. However, this strategy is usually followed by a rapid viral rebound with a substantial loss of CD4 T lymphocytes because the HIV suppression with HAART does not result in reconstitution of the HIV-specific immune response. Structured treatment interruption (STI) has already been investigated in HIV-infected subjects with well-controlled viral replication (initiating treatment during primary or chronic HIV infection) and in those with multiple treatment failures. A clear benefit of STI in patients with chronic infection remains controversial and these benefits are more often observed in patients starting treatment during primary HIV infection.

(PDF emailed within 0-6 h: $19.90)

Accession: 012708689

Download citation: RISBibTeXText

PMID: 16816398

DOI: 10.1093/jac/dkl268

Related references

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences of the United States of America 98(23): 13288-13293, 2001

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. Aids Research and Human Retroviruses 20(12): 1283-1288, 2005

Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. Journal of Acquired Immune Deficiency Syndromes 46(1): 39-47, 2007

Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. Journal of Medical Microbiology 58(Pt 1): 121-124, 2009

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS (Hagerstown) 14(18): 2857-2867, 22 December, 2000

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. Aids 14(18): 2857-2867, 2001

Efficacy of tenofovir treatment interruptions for SIV-infected infant macaques. Journal of Medical Primatology 30(4): 231, August, 2001

Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. European Journal of Medical Research 10(2): 56-62, 2005

Medicare D has big impact on HIV treatment interruptions. Decreased access to meds, six-fold increase in interruptions. Aids Alert 23(11): 121-123, 2008

The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients. Aids 17(4): 631-633, 2003

Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children. Aids and Behavior 17(1): 193-202, 2013

Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological and virological consequences. La Revue de Medecine Interne 24(6): 350-357, 2003

CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. Aids 23(7): 799-807, 2009

Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. Journal of Virology 76(23): 12344-12348, December, 2002

Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. Journal of Virology 80(13): 6399-6410, 2006